Core Scientific’s (CORZ) Overweight Rating Reiterated at Cantor Fitzgerald

Core Scientific (NASDAQ:CORZ)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued on Wednesday, Benzinga reports. They presently have a $39.00 target price on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 169.90% from the company’s current price.

Several other equities analysts have also weighed in on CORZ. Citigroup reaffirmed a “market outperform” rating on shares of Core Scientific in a report on Wednesday. Needham & Company LLC increased their price target on shares of Core Scientific from $29.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. UBS Group restated a “market outperform” rating on shares of Core Scientific in a research report on Wednesday. Wells Fargo & Company began coverage on shares of Core Scientific in a report on Thursday, September 17th. They issued an “overweight” rating and a $28.00 price objective for the company. Finally, B. Riley Financial upped their price objective on shares of Core Scientific from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.36.

Core Scientific Price Performance

CORZ stock traded up $0.94 during trading on Wednesday, hitting $14.45. 33,742,997 shares of the company traded hands, compared to its average volume of 12,695,081. The stock’s 50-day simple moving average is $17.58 and its 200 day simple moving average is $21.05. The company has a market cap of $4.64 billion, a PE ratio of -3.27 and a beta of 5.49. Core Scientific has a 1 year low of $12.31 and a 1 year high of $30.46.

Core Scientific (NASDAQ:CORZ) last announced its quarterly earnings results on Tuesday, July 28th. The company reported ($3.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($3.26). The business had revenue of $164.20 million during the quarter, compared to the consensus estimate of $144.83 million. Research analysts expect that Core Scientific will post -1.36 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Elizabeth Crain purchased 6,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was purchased at an average cost of $18.33 per share, for a total transaction of $109,980.00. Following the completion of the transaction, the director owned 71,348 shares of the company’s stock, valued at $1,307,808.84. This trade represents a 9.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Todd M. Duchene sold 10,000 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $15.12, for a total value of $151,200.00. Following the completion of the transaction, the insider directly owned 1,159,668 shares of the company’s stock, valued at approximately $17,534,180.16. This represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders bought 19,000 shares of company stock worth $342,290 and sold 100,000 shares worth $1,881,300. 1.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Core Scientific

A number of large investors have recently modified their holdings of the business. State of Alaska Department of Revenue raised its position in shares of Core Scientific by 36.7% in the third quarter. State of Alaska Department of Revenue now owns 17,493 shares of the company’s stock valued at $279,000 after buying an additional 4,701 shares during the last quarter. Reliant Investment Management LLC acquired a new position in Core Scientific during the third quarter worth about $336,000. CoreCap Advisors LLC boosted its position in Core Scientific by 205.6% during the third quarter. CoreCap Advisors LLC now owns 4,355 shares of the company’s stock worth $70,000 after acquiring an additional 2,930 shares during the last quarter. Moody National Bank Trust Division grew its stake in Core Scientific by 83.0% during the 3rd quarter. Moody National Bank Trust Division now owns 114,699 shares of the company’s stock valued at $1,833,000 after acquiring an additional 52,039 shares in the last quarter. Finally, Byrne Asset Management LLC purchased a new stake in Core Scientific during the 3rd quarter valued at about $225,000.

Key Headlines Impacting Core Scientific

Here are the key news stories impacting Core Scientific this week:

• Positive Sentiment: Analysts reaffirm bullish ratings and high price targets. Canaccord Genuity reaffirmed a “buy” rating with a $36 target, while BTIG Research maintained its “buy” rating with a $38 target. Cantor Fitzgerald also reiterated an “overweight” rating and a $39 target. These targets imply substantial potential upside from recent trading levels and reinforce expectations that Core Scientific’s AI/HDC infrastructure strategy can generate significant growth.
• Positive Sentiment: Needham maintained its $35 target. The firm reiterated its outlook even as investors monitor credit pressure affecting CoreWeave, Core Scientific’s tenant. Maintaining the target suggests Needham believes the long-term data-center opportunity remains attractive despite customer-related risks. Needham reiterates $35 Core Scientific target as tenant CoreWeave faces credit pressure
• Neutral Sentiment: Third-quarter results are scheduled for November 5. Core Scientific will release fiscal third-quarter 2026 results before the market opens and hold a conference call at 8:30 a.m. Eastern time. The event provides a near-term catalyst, particularly for updates on AI/HDC colocation demand, customer concentration, capacity expansion and financial performance. Core Scientific schedules third-quarter 2026 earnings release
• Negative Sentiment: An insider sold $151,200 of stock. Director or insider Todd DuChene sold 10,000 shares at an average price of $15.12, reducing his direct holdings by approximately 0.85%. He still retains a sizable position, but the transaction may weigh modestly on sentiment because it signals some insider profit-taking.
• Negative Sentiment: CoreWeave’s credit concerns remain a risk. Because Core Scientific relies on large data-center customers, financial pressure at CoreWeave could raise concerns about customer concentration, contract execution or payment risk. Investors will likely seek clarification on this issue during the upcoming earnings call.

About Core Scientific

Core Scientific, Inc is a digital infrastructure company that develops and operates data centers in the United States. Its business has historically centered on cryptocurrency mining, particularly the processing of transactions on the Bitcoin network, while also providing hosting and infrastructure services to other mining and technology customers.

The company is expanding its data center capabilities to support high-performance computing and artificial intelligence workloads. Its services include data center operations, power and equipment management, hosting, and related infrastructure support for customers that require substantial computing capacity.

Core Scientific was founded in 2017 and became a publicly traded company through a business combination in 2022.